Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on sequential or concomitant rechallenge to resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Cabrales, Pedro, Reid, Tony, Degesys, Aiste, Jenkins, John, Brzezniak, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: January, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772628/
https://www.ncbi.nlm.nih.gov/pubmed/26933421
http://dx.doi.org/10.1159/000443725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772628/
https://www.ncbi.nlm.nih.gov/pubmed/26933421
http://dx.doi.org/10.1159/000443725

Ejemplares similares